BridgeBio Pharma shares fall 1.95% after-hours following an investor webinar announcement.

miércoles, 3 de septiembre de 2025, 4:18 pm ET1 min de lectura
BBIO--
Bridgebio Pharma, Inc. declined 1.95% in after-hours trading, following the announcement that the company will host an investor webinar on September 10, 2025, featuring Dr. Rachel Gafni, who will provide an overview of autosomal dominant hypocalcemia type 1 (ADH1) and the Company’s Phase 3 clinical trial, CALIBRATE.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios